Portal Veterinary medicinal products

The availability of GS-441524 by pharmacies has raised questions. The French agency for veterinary medicinal products (ANMV) has long been involved in the issue of the therapeutic gap related to feline infectious peritonitis (FIP), in collaboration with the Monitoring committee for veterinary medicinal products. In particular, it has worked to ensure that the use of Remdesivir is not excluded in veterinary medicine at European level. At the same time, the ANMV informed stakeholders of the various legal gateways to therapeutic solutions, including dispensers' preparations.

Paragraph 13 of Article 58 of European Regulation 2019/06 states that the marketing authorisation holder must inform the competent authorities in advance of any cessation of marketing of a veterinary medicinal product, of the reasons justifying it and of any action he intends to take.

EU4H11 (Joint Action on quality of medicines and implementation of the pharmaceutical legislation/strategy) is part of the EU4Health programme funded by the European Commission. The total budget of this Joint Action amounts to more than 3 million EUR, 80% of the costs will be co-financed by the European Commission. The project aims at strengthening capacities of EU/EEA GMP/GDP inspectorates in the global vision of mutual reliance of inspection data to better ensure quality of medicinal products and protection of Public Health.